Central Virginia

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

Mission Secure Inc. recently announced the closing of an $8 million Series A financing round led by Energy Innovation Capital and Chevron Technology Ventures.

UVA, Albemarle County, and the City of Charlottesville pledged support for a program aimed at accelerating the growth of local startups.

A WMRA podcast alludes to UVA's role in the biotechnology industry in Central Virginia.

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

The CvilleBioHub invites the biotechnology community to a reception with next generation scientists enrolled in UVA's Biotechnology Training Program.

UVA will receive funding to train teams of students and faculty research scientists to inspire effective innovation and entrepreneurial thinking.

UVA will receive funding to train teams of students and faculty research scientists to inspire effective innovation and entrepreneurial thinking.